NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Egetis Therapeutics AB (publ) (ST: EGTX)
EGTX Technical Analysis
4
As on 14th Jan 2025 EGTX STOCK Price closed @ 5.89 and we RECOMMEND Buy for LONG-TERM with Stoploss of 5.68 & Strong Buy for SHORT-TERM with Stoploss of 4.31 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EGTXSTOCK Price
Open | 5.94 | Change | Price | % |
High | 6.10 | 1 Day | -0.01 | -0.17 |
Low | 5.83 | 1 Week | -1.21 | -17.04 |
Close | 5.89 | 1 Month | 0.25 | 4.43 |
Volume | 423834 | 1 Year | 1.58 | 36.66 |
52 Week High 9.18 | 52 Week Low 3.91 |
ST Sweden Most Active Stocks
FING-B | 0.04 | 0.00% |
QLINEA | 0.50 | 284.62% |
HDW-B | 0.00 | % |
LIPI | 0.25 | -7.41% |
SBB-B | 4.91 | 0.61% |
LUNE | 21.97 | 6.65% |
WYLD | 0.01 | 0.00% |
ENERS | 0.00 | % |
KLAR | 0.61 | -8.96% |
NIBE-B | 38.72 | -2.64% |
ST Sweden Top Gainers Stocks
ST Sweden Top Losers Stocks
EGTX Daily Charts |
EGTX Intraday Charts |
Whats New @ Bazaartrend |
EGTX Free Analysis |
|
EGTX Important Levels Intraday
RESISTANCE | 6.41 |
RESISTANCE | 6.24 |
RESISTANCE | 6.14 |
RESISTANCE | 6.04 |
SUPPORT | 5.74 |
SUPPORT | 5.64 |
SUPPORT | 5.54 |
SUPPORT | 5.37 |
EGTX Forecast January 2025
4th UP Forecast | 7.68 |
3rd UP Forecast | 7.11 |
2nd UP Forecast | 6.75 |
1st UP Forecast | 6.4 |
1st DOWN Forecast | 5.38 |
2nd DOWN Forecast | 5.03 |
3rd DOWN Forecast | 4.67 |
4th DOWN Forecast | 4.1 |
EGTX Weekly Forecast
4th UP Forecast | 7.20 |
3rd UP Forecast | 6.78 |
2nd UP Forecast | 6.52 |
1st UP Forecast | 6.26 |
1st DOWN Forecast | 5.52 |
2nd DOWN Forecast | 5.26 |
3rd DOWN Forecast | 5.00 |
4th DOWN Forecast | 4.58 |
EGTX Forecast2025
4th UP Forecast | 16.43 |
3rd UP Forecast | 13.05 |
2nd UP Forecast | 10.96 |
1st UP Forecast | 8.87 |
1st DOWN Forecast | 2.91 |
2nd DOWN Forecast | 0.82 |
3rd DOWN Forecast | -1.27 |
4th DOWN Forecast | -4.65 |
Egetis Therapeutics AB (publ) ( ST Sweden Symbol : EGTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EGTX Other Details
Segment | EQ | |
Market Capital | 949146688.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
EGTX Address
EGTX Latest News
EGTX Business Profile
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was founded in 2006 and is based in Stockholm, Sweden. Address: Grev Turegatan 11c, Stockholm, Sweden, 114 46
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service